




PHARMACEUTICAL 2018

Marker Therapeutics Inc.
Rank 293 of 342





PHARMACEUTICAL 2018

Marker Therapeutics Inc.
Rank 293 of 342

The relative strengths and weaknesses of Marker Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Marker Therapeutics Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 28% points. The greatest weakness of Marker Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 201% points.

The company's Economic Capital Ratio, given in the ranking table, is -140%, being 186% points below the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	5,180
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,522
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	681
Other Revenues	0
Property and Equipment	0
Research and Development	5,251
Selling, General and Administrative Expense	6,412

Output Variable	Value in 1000 USD
Assets	5,180
Liabilities	1,522
Expenses	11,663
Revenues	0
Stockholders Equity	3,658
Net Income	-10,982
Comprehensive Net Income	-10,982
Economic Capital Ratio	-140%